Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

101. Comparing the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis: a randomized controlled trial Full Text available with Trip Pro

Comparing the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis: a randomized controlled trial To evaluate the effect of Cawthorne-Cooksey and Frenkel exercises on balance in patients with multiple sclerosis.It was a three-arm parallel randomized controlled trial study.Outpatient clinic.Patients with multiple sclerosis.Subjects in the intervention groups completed a 12-week program consisted of Cawthorne-Cooksey or Frenkel exercises. The control (...) Balance Scale score increased to 8.9 in the Cawthorne-Cooksey group and 2.3 in the Frenkel group, while it decreased to 1.2 in the control group. When comparing inter-group changes, Berg Balance Scale showed significant improvements in favor of the Cawthorne-Cooksey group after the intervention ( P < 0.05).This study demonstrated that in comparison with Frenkel and the control groups, a program of Cawthorne-Cooksey exercise is more effective in improving balance in patients with multiple sclerosis.

2017 EvidenceUpdates

102. Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment

Daclizumab (Zinbryta) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment Daclizumab (Zinbryta▼) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment - GOV.UK GOV.UK uses cookies to make the site simpler. Search Daclizumab (Zinbryta▼) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients (...) and recall of daclizumab (Zinbryta▼) in the EU following reports of serious inflammatory brain disorders, including encephalitis and meningoencephalitis, in patients with multiple sclerosis. See for more information. Post-publication note; 12 January 2018 The EU-wide review of daclizumab has now concluded. See the for the restricted indication, new precautions for use, and revised monitoring requirements. Review of patients Healthcare professionals should review promptly any patients who are currently

2017 MHRA Drug Safety Update

103. Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis Full Text available with Trip Pro

Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis Regulatory agencies often request prospective, product-specific post-authorization pregnancy exposure registries to monitor safety during pregnancy, even though studies using existing health databases could also be employed.Using multiple sclerosis (MS) as a case study, we evaluated various study designs and data sources previously used to study medication

2017 Drugs - real world outcomes

104. Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial Full Text available with Trip Pro

Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial Multiple Sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system. Oxidative stress plays a major role in the onset and progression of MS. Asymmetric dimethylarginine (ADMA) formation is dependent on oxidative stress status.We examined whether alpha-lipoic acid (ALA) as a potent antioxidant could improve the Expanded Disability (...) Status Scale (EDSS) and decrease plasma level of ADMA in multiple sclerosis patients.In a randomized, double-blinded clinical trial conducted at Sina Hospital in Tehran, Iran, from September 2009 to July 2011, 24 patients with relapsing-remitting MS were divided into a treatment group receiving ALA (1200mg/day) for 12 weeks and a control group receiving placebo. Then patients' EDSS and Plasma levels of ADMA were measured at baseline and 12 weeks later. Statistical analysis was done by SPSS software

2017 Electronic physician Controlled trial quality: uncertain

105. Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years)

Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search (...) will not return all technologies currently in development as these outputs are produced as required for our stakeholders. > > > Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years) July 2017 The current treatment is already licensed in adults, but is currently in a phase III trial for the treatment of multiple sclerosis in paediatric patients. Fingolimod

2017 NIHR Innovation Observatory

106. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial Full Text available with Trip Pro

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now describe the results of the MS-STAT cognitive substudy (...) with comprehensive longitudinal cognitive, neuropsychiatric, and HRQoL assessments. We found evidence of a positive effect of simvastatin on frontal lobe function and a physical quality-of-life measure. Although we found no effect of simvastatin on the other outcome measures, these potential effects warrant confirmation and underline the importance of fully assessing cognition and quality of life in progressive multiple sclerosis treatment trials.The Moulton Foundation, the Berkeley Foundation, the Multiple

2017 EvidenceUpdates

107. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina]

[Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Klappenbach R, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A. [Dimethyl fumarate in multiple sclerosis: Comparison among different commercially available trademarks in Argentina] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe

2017 Health Technology Assessment (HTA) Database.

108. Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. Full Text available with Trip Pro

Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis. On the basis of encouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocycline reduces the risk of conversion from a first demyelinating event (also known as a clinically isolated syndrome) to multiple sclerosis.During the period from January 2009 through July 2013, we randomly assigned participants who had had their first demyelinating symptoms within the previous 180 (...) days to receive either 100 mg of minocycline, administered orally twice daily, or placebo. Administration of minocycline or placebo was continued until a diagnosis of multiple sclerosis was established or until 24 months after randomization, whichever came first. The primary outcome was conversion to multiple sclerosis (diagnosed on the basis of the 2005 McDonald criteria) within 6 months after randomization. Secondary outcomes included conversion to multiple sclerosis within 24 months after

2017 NEJM Controlled trial quality: predicted high

109. Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy Full Text available with Trip Pro

Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy - GOV.UK GOV.UK uses cookies to make the site simpler. Search Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy Healthcare professionals should report any suspected adverse effects relating to fingolimod (Gilenya▼) or other treatments for multiple sclerosis, including (...) suspected adverse effects occurring after discontinuation, via the Yellow Card Scheme. Published 24 April 2017 From: Therapeutic area: We are aware of two recently published articles describing a suspected rebound syndrome (clinical and radiological signs of severe exacerbation beyond what was expected for that patient prior to discontinuation or treatment change) in patients with multiple sclerosis after treatment with fingolimod (Gilenya▼) was stopped, some of whom were switched to other treatments

2017 MHRA Drug Safety Update

110. Ocrevus (ocrelizumab) Injection - To treat patients with relapsing and primary progressive forms of multiple sclerosis

Ocrevus (ocrelizumab) Injection - To treat patients with relapsing and primary progressive forms of multiple sclerosis Ocrevus (ocrelizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search Ocrevus (ocrelizumab) Injection Ocrevus Company: Genentech, Inc. Application No.: 761053 Approval Date: 03/28/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2017 FDA - Drug Approval Package

111. Daclizumab for treating relapsing?remitting multiple sclerosis

Daclizumab for treating relapsing?remitting multiple sclerosis Daclizumab for treating relapsing–remitting multiple sclerosis | Guidance | NICE Daclizumab for treating relapsing–remitting multiple sclerosis Technology appraisal guidance [TA441] Published date: 26 April 2017 Guidance This guidance has been withdrawn because Biogen is withdrawing its marketing authorisations for daclizumab. See the European Medicines Agency’s . Explore © NICE [year]. All rights reserved. Subject to .

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

112. Assessment of the diagnostic accuracy of double inversion recovery sequence compared with FLAIR and T2W_TSE in detection of cerebral multiple sclerosis lesions Full Text available with Trip Pro

Assessment of the diagnostic accuracy of double inversion recovery sequence compared with FLAIR and T2W_TSE in detection of cerebral multiple sclerosis lesions Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. MRI has an important role in early diagnosis of MS within diagnostic criteria.To determine the diagnostic value of the double inversion recovery (DIR) sequence in detection of brain MS lesions.In this cross-sectional study, 55 patients were admitted

2017 Electronic physician

113. Multiple Sclerosis

Multiple Sclerosis ©Institute for Clinical and Economic Review, 2017 Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value Final Evidence Report March 6, 2017 Prepared for ©Institute for Clinical and Economic Review, 2017 Page i Final Evidence Report – DMTs for RRMS and PPMS ICER Staff and Consultants University of Washington School of Pharmacy Modeling Group Jeffrey A. Tice, MD Professor of Medicine University of California (...) 148 Appendix E. Comparative Value Supplemental Information 166 Appendix F. Patient Survey Questions 204 Appendix G. Public Comments 210 Appendix H. Conflict of Interest Disclosures 216 ©Institute for Clinical and Economic Review, 2017 Page vi Final Evidence Report – DMTs for RRMS and PPMS List of Acronyms Used in this Report AHRQ Agency for Healthcare Research and Quality BID Twice daily CDMS Clinically definite multiple sclerosis CI Confidence interval CIS Clinically isolated syndrome CNS Central

2017 California Technology Assessment Forum

114. Portable neuromodulation stimulator for multiple sclerosis

Portable neuromodulation stimulator for multiple sclerosis Portable neuromodulation stimulator for multiple sclerosis | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced (...) as required for our stakeholders. > > > Portable neuromodulation stimulator for multiple sclerosis Portable neuromodulation stimulator for multiple sclerosis March 2017 The Portable Neuromodulation Stimulator or PoNS™, developed by Helius Medical Technologies, is a non-invasive device that is designed to deliver neurostimulation through the tongue to improve balance and gait in patients with advanced multiple sclerosis (MS). The device is intended to be used as part of targeted functional therapy called

2017 NIHR Innovation Observatory

115. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. (Abstract)

Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Emerging evidence suggests that living near major roads might adversely affect cognition. However, little is known about its relationship with the incidence of dementia, Parkinson's disease, and multiple sclerosis. We aimed to investigate the association between residential proximity to major roadways and the incidence of these three neurological diseases (...) in Ontario, Canada.In this population-based cohort study, we assembled two population-based cohorts including all adults aged 20-50 years (about 4·4 million; multiple sclerosis cohort) and all adults aged 55-85 years (about 2·2 million; dementia or Parkinson's disease cohort) who resided in Ontario, Canada on April 1, 2001. Eligible patients were free of these neurological diseases, Ontario residents for 5 years or longer, and Canadian-born. We ascertained the individual's proximity to major roadways

2017 Lancet

116. Ocrevus - ocrelizumab - Primary progressive multiple sclerosis

Ocrevus - ocrelizumab - Primary progressive multiple sclerosis ocrelizumab | CADTH.ca Find the information you need ocrelizumab ocrelizumab Last Updated: May 9, 2018 Result type: Reports Project Number: SR0542-000 Product Line: Generic Name: ocrelizumab Brand Name: Ocrevus Manufacturer: Hoffman-La Roche Limited Indications: Primary progressive multiple sclerosis Submission Type: New Indication Project Status: Complete Biosimilar: No Date Recommendation Issued: April 26, 2018 Recommendation Type (...) to applicant and drug plans April 05, 2018 Embargo period ended and validation of redacted CDR review report(s) received April 19, 2018 CDEC Final Recommendation issued to applicant and drug plans April 26, 2018 CDEC Final Recommendation posted April 30, 2018 Final CDR review report(s) and patient input posted May 08, 2018 Tags multiple sclerosis, multiple sclerosis, chronic progressive, multiple sclerosis, relapsing-remitting, Ocrevus; ocrelizumab; PPMS; primary progressive multiple sclerosis Files Follow

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review